Patient clinical characteristics (n = 28)
| Characteristic | No. of patients (%) |
|---|---|
| Mean age, years (SD) | 63 (10) |
| Male sex | 20 (71) |
| Cancer type | |
| Melanoma | 7 (25) |
| Renal cell carcinoma | 4 (14) |
| Prostate carcinoma | 4 (14) |
| Urothelial | 3 (11) |
| Other solid tumors | 10 (36) |
| Cancer stage | |
| III | 6 (21) |
| IV | 22 (79) |
| ICI type | |
| CTLA-4 | 8 (29) |
| PD-1/L1 | 12 (43) |
| Combination | 8 (29) |
| Median no. of ICI infusions (IQR) | 3 (1–36) |
| Median time to diarrhea onset, weeks (IQR) | 10 (1–70) |
| Peak CTCAE grade of diarrhea | |
| 2 | 15 (54) |
| 3–4 | 13 (46) |
| Peak CTCAE grade of colitis | |
| 1–2 | 16 (57) |
| 3–4 | 12 (43) |
| Colitis symptoms | |
| Abdominal pain | 14 (50) |
| Blood or mucous in stool | 11 (39) |
| Other adverse events | |
| Dermatological | 4 (14) |
| Endocrine | 2 (7) |
| Musculoskeletal | 2 (7) |
| Pulmonary | 1 (4) |
| Pancreatic | 1 (4) |
Abbreviations: SD, standard deviation; ICI, immune checkpoint inhibitor; IQR, interquartile range; CTCAE, Common Terminology Criteria of Adverse Events